ClinicalTrials.gg

Program

CHS-1420

A development code.

Its studies are mostly in Psoriasis, led by 2 companies.

Furthest: phase 3, since Jul 1, 20152 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Coherus Biosciences10 open or runningphase 3since Jul 1, 2015Jul 1, 2015none ahead
Nanjing King-Friend Biochemical Pharmaceutical10 open or runningphase 1since Aug 12, 2025Aug 12, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 1, 2015First study: phase 3 study in Plaque PsoriasisNew to Coherus BiosciencesCoherus Biosciences · NCT02489227 · 545 enrolled · United States, Bulgaria, Canada and more
  2. Aug 12, 2025Nanjing King-Friend Biochemical Pharmaceutical’s first study: phase 1 study in Healthy ParticipantsNew to Nanjing King-Friend Biochemical PharmaceuticalNanjing King-Friend Biochemical Pharmaceutical · NCT07147257 · 238 enrolled · China

TargetBeta

TNF →read by rule
“TNF-alpha inhibitor”ChEMBL 37, by rule

Other programs on TNF

ProgramCompanyFurthest phaseStudies
AdalimumabruleAbbottphase 4153
Brentuximab VedotinrulePfizerphase 437
brivekimigSanofiphase 26
Hadlimarulebiora-therapeutics-incphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07147257Healthy Participants · China1CompletedNanjing King-Friend Biochemical PharmaceuticalMay 6, 2025238
NCT02489227Plaque Psoriasis · United States, Bulgaria, Canada and more3CompletedCoherus BiosciencesMay 6, 2016545

How it is read

Names in the registry

  • “CHS-1420”, 2 entries

Codes read as this program: CHS1420.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.